A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism.
- Authors
- Loukola, Anu; Buchwald, Jadwiga; Gupta, Richa; Palviainen, Teemu; HΓ€llfors, Jenni; Tikkanen, Emmi; Korhonen, Tellervo; Ollikainen, Miina; Sarin, Antti-Pekka; Ripatti, Samuli; LehtimΓ€ki, Terho; Raitakari, Olli; Salomaa, Veikko; Rose, Richard J; Tyndale, Rachel F; Kaprio, Jaakko
- Year
- 2015
- Journal
- PLoS genetics
- PMID
- 26407342
- DOI
- 10.1371/journal.pgen.1005498
- PMCID
- PMC4583245
Individuals with fast nicotine metabolism typically smoke more and thus have a greater risk for smoking-induced diseases. Further, the efficacy of smoking cessation pharmacotherapy is dependent on the rate of nicotine metabolism. Our objective was to use nicotine metabolite ratio (NMR), an established biomarker of nicotine metabolism rate, in a genome-wide association study (GWAS) to identify novel genetic variants influencing nicotine metabolism. A heritability estimate of 0.81 (95% CI 0.70-0.88) was obtained for NMR using monozygotic and dizygotic twins of the FinnTwin cohort. We performed a GWAS in cotinine-verified current smokers of three Finnish cohorts (FinnTwin, Young Finns Study, FINRISK2007), followed by a meta-analysis of 1518 subjects, and annotated the genome-wide significant SNPs with methylation quantitative loci (meQTL) analyses. We detected association on 19q13 with 719 SNPs exceeding genome-wide significance within a 4.2 Mb region. The strongest evidence for association emerged for CYP2A6 (min p = 5.77E-86, in intron 4), the main metabolic enzyme for nicotine. Other interesting genes with genome-wide significant signals included CYP2B6, CYP2A7, EGLN2, and NUMBL. Conditional analyses revealed three independent signals on 19q13, all located within or in the immediate vicinity of CYP2A6. A genetic risk score constructed using the independent signals showed association with smoking quantity (p = 0.0019) in two independent Finnish samples. Our meQTL results showed that methylation values of 16 CpG sites within the region are affected by genotypes of the genome-wide significant SNPs, and according to causal inference test, for some of the SNPs the effect on NMR is mediated through methylation. To our knowledge, this is the first GWAS on NMR. Our results enclose three independent novel signals on 19q13.2. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in NMR in these study samples. Further, we provide evidence for plausible epigenetic mechanisms influencing NMR.
Manhattan plot of the GWAS meta-analysis results of the three Finnish cohorts. The horizontal line represents the genome-wide significance threshold (p<5E-08).
Regional plot of 19q13.2.(A) In the GWAS meta-analysis a minimum p-value of 5.77E-86 was obtained for rs56113850, in intron 4 of CYP2A6. (B) Analyses conditioned on the top-SNP (rs56113850) revealed rs113288603 as a second independent genome-wide significant signal (pcond = 7.03E-25). (C) Analyses conditioned on the two independent SNPs (rs56113850, rs113288603) revealed esv2663194 as a third independent genome-wide significant signal (pcond = 9.3E-17). (D) Analyses conditioned on the three independent SNPs yielded no additional signal exceeding the genome-wide significance threshold. All plots are generated with LocusTrack [52]. LD (R2) values were obtained from the FINRISK sample (N = 19857).
| Name | Type |
|---|---|
| 1000 Genomes Phase I integrated haplotypes local | cohort |
| 1000 Genomes Project | cohort |
| 19q13.2 local | variant |
| 2010 GWAS meta-analysis of smoking quantity local | cohort |
| 32 kb deletion local | variant |
| 3-hydroxycotine local | drug |
| 3-hydroxycotinine | drug |
| 3-hydroxycotinine-glucuronide local | drug |
| 3-hydroxycotinine phenotype local | phenotype |
| 3-SNP wGRS local | variant |
| 4-SNP wGRS local | variant |
| 719 genome-wide significant SNPs local | variant |
| -83C>T local | variant |
| age | phenotype |
| alcohol | phenotype |
| alcoholism | phenotype |
| Alcohol Use | phenotype |
| Angina pectoris local | phenotype |
| asthma | phenotype |
| BMI | phenotype |
| body mass index | phenotype |
| brain | anatomy |
| breath CO local | phenotype |
| Broad Institute of MIT and Harvard local | cohort |
| bronchitis | phenotype |
| bupropion | drug |
| cancer | phenotype |
| carbon monoxide | drug |
| cardiovascular disease | phenotype |
| Cardiovascular illness local | phenotype |
| Caucasian (Finns) local | phenotype |
| Caucasian population | cohort |
| Caucasians | cohort |
| Cessation pharmacotherapy local | drug |
| cg08551532 local | variant |
| Cigarette consumption local | drug |
| cigarettes | phenotype |
| cigarette smoke exposure local | drug |
| clearance rate local | phenotype |
| common variants | cohort |
| cortex | anatomy |
| cotinine | drug |
| cotinine-glucuronide local | drug |
| Cotinine phenotype local | phenotype |
| coumarin | drug |
| CPD | phenotype |
| CPD meta-analysis (N=85997) local | cohort |
| current daily smoking | phenotype |
| current smoking | phenotype |
| CYP2A13 local | gene |
| CYP2A6 | gene |
| CYP2A6*10 local | variant |
| CYP2A6*14 local | variant |
| CYP2A6*18 local | variant |
| CYP2A6*21 local | variant |
| CYP2A6*35 local | variant |
| CYP2A6 variant local | variant |
| CYP2A7 | gene |
| CYP2B6 | gene |
| CYP2B6*4 local | variant |
| CYP2B6*9 local | variant |
| CYP2F1 local | gene |
| Cytochrome P450 gene family local | gene |
| decreased clearance rate local | phenotype |
| Dizygotic individuals local | cohort |
| DLL3 | gene |
| DNA methylation | drug |
| DNA methylation levels local | phenotype |
| dopamine | drug |
| DSM-IV major depressive disorder local | phenotype |
| EGLN2 local | gene |
| enzyme | drug |
| estrogen | drug |
| Estrogen containing contraceptive pills local | drug |
| esv2663194 local | variant |
| ever smoking | phenotype |
| Fast metabolism local | phenotype |
| fast metabolizer local | phenotype |
| Finnish cohort | cohort |
| Finnish GWAS data local | cohort |
| Finnish population | cohort |
| FinnTwin local | cohort |
| Finntwin12 | cohort |
| FinnTwin16 local | cohort |
| FinnTwin sample local | cohort |
| FINRISK local | cohort |
| FINRISK1992 local | cohort |
| FINRISK 1992 cohort local | cohort |
| FINRISK1997 local | cohort |
| FINRISK 1997 cohort local | cohort |
| FINRISK2002 local | cohort |
| FINRISK 2002 cohort local | cohort |
| FINRISK2007 local | cohort |
| FINRISK 2007 cohort local | cohort |
| former smokers | phenotype |
| functional variant | variant |
| genomic control inflation factor Ξ» local | drug |
| Genotyping batch local | phenotype |
| GWAS meta-analysis sample local | cohort |
| HCC | phenotype |
| Heart failure local | phenotype |
| hormone replacement therapy | drug |
| Human670-QuadCustom Illumina BeadChip | drug |
| Illumina Human Core Exome BeadChip local | drug |
| Impute2 | drug |
| Infinium 450k Methylation BeadChip local | cohort |
| initiation | phenotype |
| Institute for Molecular Medicine local | cohort |
| intermediate nicotine metabolizer local | phenotype |
| lifetime smoking | phenotype |
| lung cancer | phenotype |
| major depression disorder local | phenotype |
| Major depression disorder local | phenotype |
| major depressive disorder | phenotype |
| Mesolimbic brain reward pathway local | anatomy |
| Monozygotic individuals local | cohort |
| NAG-FIN local | cohort |
| NAG-FIN sample local | cohort |
| nicotine | drug |
| Nicotine Addiction Genetics consortium local | cohort |
| nicotine clearance | phenotype |
| nicotine dependence | phenotype |
| nicotine metabolism | phenotype |
| nicotine metabolite ratio | phenotype |
| nicotine patch | drug |
| NMR | drug |
| NMR GWAS local | cohort |
| Normal metabolizers local | phenotype |
| normal nicotine metabolizer local | phenotype |
| nornicotine local | drug |
| NOTCH3 local | gene |
| novel independent SNPs local | variant |
| nucleus accumbens | anatomy |
| NUMBL local | gene |
| Older Finnish Twin Cohort local | cohort |
| Pulmonary emphysema local | phenotype |
| quantity | phenotype |
| race/ethnicity | phenotype |
| rare variant | cohort |
| Reduced activity CYP2A6 variants local | variant |
| reduced-activity variants local | variant |
| regular smoking | phenotype |
| risk factor | phenotype |
| rs113288603 local | variant |
| rs12461964 local | variant |
| rs2279343 local | variant |
| rs28602288 local | variant |
| rs3211371 local | variant |
| rs3745274 local | variant |
| rs4105144 | variant |
| rs4802082 local | variant |
| rs56113850 local | variant |
| rs7260329 local | variant |
| rs76443752 local | variant |
| sex | phenotype |
| SHAPEIT2 | drug |
| Side-effects local | phenotype |
| slow metabolizer | phenotype |
| Slow metabolizers local | phenotype |
| slow nicotine metabolizer local | phenotype |
| smoking | phenotype |
| smoking behavior | phenotype |
| smoking cessation | phenotype |
| Smoking-induced diseases local | phenotype |
| smoking quantity | phenotype |
| smoking status | phenotype |
| SNP | cohort |
| Spaniards local | cohort |
| study cohort | cohort |
| top-SNPs (common) local | variant |
| Twin cohort | cohort |
| UGT enzymes local | gene |
| University of Helsinki local | cohort |
| varenicline | drug |
| Weighted genetic risk score (wGRS) local | drug |
| Welcome Trust Sanger Institute local | cohort |
| wGRS local | drug |
| wGRS local | variant |
| wild-type CYP2A6 allele local | variant |
| YFS | cohort |
No uploaded files.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| 1000 Genomes Project Consortium, AbecasisGR, Auton ABrooks LD, DePristoMA, DurbinRM, et al An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422): 56β65. 10.1038/nature11632 23128226PMC3498066 | β | β | β |
| Al KoudsiN, MwenifumboJC, SellersEM, BenowitzNL, SwanGE, TyndaleRF. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol. 2006;62(6): 481β84. 1675826510.1007/s00228-006-0113-3 | β | β | β |
| AlmliLM, StevensJS, SmithAK, KilaruV, MengQ, FloryJ, et al A genome-wide identified risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical activation to fearful faces. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(5): 327β36. 10.1002/ajmg.b.32315 25988933PMC4844461 | β | β | β |
| AryeeMJ, JaffeAE, Corrada-BravoH, Ladd-AcostaC, FeinbergAP, HansenKD, et al Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30(10): 1363β69. 10.1093/bioinformatics/btu049 24478339PMC4016708 | β | β | β |
| AulchenkoYS, RipkeS, IsaacsA, van DuijnCM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23(10): 1294β96. 1738401510.1093/bioinformatics/btm108 | β | β | β |
| BarrettJC, FryB, MallerJ, DalyMJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2): 263β65. 1529730010.1093/bioinformatics/bth457 | β | β | β |
| BellJT, PaiAA, PickrellJK, GaffneyDJ, Pique-RegiR, DegnerJF, et al DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011;12(1): R10 10.1186/gb-2011-12-1-r10 21251332PMC3091299 | β | β | β |
| BenjaminiY, HochbergY. Controlling the false discovery rateβA practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Metallurgy) 1995;57(1): 289β300. | β | β | β |
| BenowitzNL, HukkanenJ, JacobP3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192: 29β60. 10.1007/978-3-540-69248-5_2 19184645PMC2953858 | β | β | β |
| BenowitzNL, SwanGE, JacobP3rd, Lessov-SchlaggarCN, TyndaleRF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther. 2006;80(5): 457β67. 1711280210.1016/j.clpt.2006.08.011 | β | β | β |
| BenowitzNL. Nicotine addiction. N Engl J Med. 2010;362(24): 2295β2303. 10.1056/NEJMra0809890 20554984PMC2928221 | β | β | β |
| BenowitzNL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49: 57β71. 10.1146/annurev.pharmtox.48.113006.094742 18834313PMC2946180 | β | β | β |
| BloomAJ, BakerTB, ChenLS, BreslauN, HatsukamiD, BierutLJ, et al Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Hum Mol Genet. 2014;23(2): 555β61. 10.1093/hmg/ddt432 24045616PMC3869360 | β | β | β |
| BorodulinK, VartiainenE, PeltonenM, JousilahtiP, JuoleviA, LaatikainenT, et al Forty-year trends in cardiovascular risk factors in Finland. Eur J Public Health. 2015;25(3):539β46. 10.1093/eurpub/cku174 25422363 | β | β | β |
| BromsU, PennanenM, PatjaK, OllilaH, KorhonenT, KankaanpÀÀA, et al Diurnal Evening Type is Associated with Current Smoking, Nicotine Dependence and Nicotine Intake in the Population Based National FINRISK 2007 Study. J Addict Res Ther. 2012 1 25;S2 pii: 002 2290533210.4172/2155-6105.s2-002PMC3422076 | β | β | β |
| ChenLS, BloomAJ, BakerTB, SmithSS, PiperME, MartinezM, et al Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2014;109(1): 128β37. 10.1111/add.12353 24033696PMC3946972 | β | β | β |
| ChenowethMJ, NovalenM, HawkLWJr, SchnollRA, GeorgeTP, CinciripiniPM, et al Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9): 1773β82. 10.1158/1055-9965.EPI-14-0427 25012994PMC4154993 | β | β | β |
| ChenowethMJ, O'LoughlinJ, SylvestreMP, TyndaleRF. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet Genomics. 2013;23(4): 232β35. 10.1097/FPC.0b013e32835f834d 23462429PMC3744214 | β | β | β |
| Cuellar-PartidaG, RenteriaME, MacGregorS. LocusTrack: Integrated visualization of GWAS results and genomic annotation. Source Code Biol Med. 2015;10: 1 10.1186/s13029-015-0032-8 25750659PMC4351846 | β | β | β |
| DawoodN, VaccarinoV, ReidKJ, SpertusJA, HamidN, ParasharS, et al Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med. 2008;168(18): 1961β67. 10.1001/archinte.168.18.1961 18852396 | β | β | β |
| DelaneauO, HowieB, CoxAJ, ZaguryJF, MarchiniJ. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013;93(4): 687β96. 10.1016/j.ajhg.2013.09.002 24094745PMC3791270 | β | β | β |
| DemirkanA, HennemanP, VerhoevenA, DharuriH, AminN, van KlinkenJB, et al Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. PLoS Genet. 2015;11(1): e1004835 10.1371/journal.pgen.1004835 25569235PMC4287344 | β | β | β |
| DempseyD, TutkaP, JacobP3rd, AllenF, SchoedelK, TyndaleRF, et al Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1): 64β72. 1522946510.1016/j.clpt.2004.02.011 | β | β | β |
| DempseyDA, St HelenG, JacobP3rd, TyndaleRF, BenowitzNL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clin Pharmacol Ther. 2013;94(6): 687β94. 10.1038/clpt.2013.159 23933970PMC3834081 | β | β | β |
| DickDM, AlievF, VikenR, KaprioJ, RoseRJ. Rutgers alcohol problem index scores at age 18 predict alcohol dependence diagnoses 7 years later. Alcohol Clin Exp Res. 2011;35(5): 1011β4. 10.1111/j.1530-0277.2010.01432.x 21323682PMC3083486 | β | β | β |
| FragkiadakiP, SoulitzisN, SifakisS, KoutroulakisD, GourvasV, VrachnisN, et al Downregulation of notch signaling pathway in late preterm and term placentas from pregnancies complicated by preeclampsia. PLoS One. 2015;10(5): e0126163 10.1371/journal.pone.0126163 25962154PMC4427301 | β | β | β |
| FukamiT, NakajimaM, HigashiE, YamanakaH, SakaiH, McLeodHL, et al Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos. 2005;33(8): 1202β10. 1590001510.1124/dmd.105.004994 | β | β | β |
| GarciaKL, CoenK, MiksysS, LΓͺAD, TyndaleRF. Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Neuropsychopharmacology. 2015;40(8):1910β8. 10.1038/npp.2015.40 25652250PMC4839514 | β | β | β |
| GrandoSA. Connections of nicotine to cancer. Nat Rev Cancer. 2014;14(6): 419β29. 10.1038/nrc3725 24827506 | β | β | β |
| Hartmann-BoyceJ, SteadLF, CahillK, LancasterT. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction. 2013;108(10): 1711β21. 10.1111/add.12291 23834141 | β | β | β |
| HigashiE, FukamiT, ItohM, KyoS, InoueM, YokoiT, et al Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007;35(10): 1935β41. 1764627910.1124/dmd.107.016568 | β | β | β |
| HofmannMH, BlievernichtJK, KleinK, SausseleT, SchaeffelerE, SchwabM, et al Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008;325(1): 284β92. 10.1124/jpet.107.133306 18171905 | β | β | β |
| HoMK, TyndaleRF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7(2): 81β98. 1722491310.1038/sj.tpj.6500436 | β | β | β |
| HowieBN, DonnellyP, MarchiniJ. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5(6): e1000529 10.1371/journal.pgen.1000529 19543373PMC2689936 | β | β | β |
| HukkanenJ, JacobP3rd, BenowitzNL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1): 79β115. 1573472810.1124/pr.57.1.3 | β | β | β |
| KaprioJ. The Finnish Twin Cohort Study: an update. Twin Res Hum Genet. 2013;16(1): 157β62. 10.1017/thg.2012.142 23298696PMC4493754 | β | β | β |
| KaprioJ. Twin studies in Finland 2006. Twin Res Hum Genet. 2006;9(6): 772β77. 1725440610.1375/183242706779462778 | β | β | β |
| KettunenJ, TukiainenT, SarinAP, Ortega-AlonsoA, TikkanenE, LyytikΓ€inenLP, et al Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet. 2012;44(3): 269β76. 10.1038/ng.1073 22286219PMC3605033 | β | β | β |
| LatvalaA, Tuulio-HenrikssonA, DickDM, VuoksimaaE, VikenRJ, SuvisaariJ, et al Genetic origins of the association between verbal ability and alcohol dependence symptoms in young adulthood. Psychol Med. 2011;41(3): 641β51. 10.1017/S0033291710001194 20529418PMC8094064 | β | β | β |
| LeaRA, DicksonS, BenowitzNL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol. 2006;30(6): 386β89. 1687257010.1093/jat/30.6.386 | β | β | β |
| LeeKW, PausovaZ. Cigarette smoking and DNA methylation. Front Genet. 2013;4: 132 10.3389/fgene.2013.00132 23882278PMC3713237 | β | β | β |
| LermanC, SchnollRA, HawkLWJr, CinciripiniP, GeorgeTP, WileytoEP, et al Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2): 131β38. 10.1016/S2213-2600(14)70294-2 25588294PMC4480925 | β | β | β |
| LermanC, TyndaleR, PattersonF, WileytoEP, ShieldsPG, PintoA, et al Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600β8. 1676514810.1016/j.clpt.2006.02.006 | β | β | β |
| LiuJZ, TozziF, WaterworthDM, PillaiSG, MugliaP, MiddletonL, et al Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42(5): 436β40. 10.1038/ng.572 20418889PMC3612983 | β | β | β |
| LoukolaA, WedenojaJ, Keskitalo-VuokkoK, BromsU, KorhonenT, RipattiS, et al Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. Mol Psychiatry. 2014;19(5): 615β24. 10.1038/mp.2013.72 23752247PMC3883996 | β | β | β |
| MaemuraK, YoshikawaH, YokoyamaK, UenoT, KuroseH, UchiyamaK, et al Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 2013;42(3): 817β22. 10.3892/ijo.2013.1778 23337976PMC3597457 | β | β | β |
| MiksysS, LermanC, ShieldsPG, MashDC, TyndaleRF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003;45(1): 122β32. 1281466510.1016/s0028-3908(03)00136-9 | β | β | β |
| MillsteinJ, ZhangB, ZhuJ, SchadtEE. Disentangling molecular relationships with a causal inference test. BMC Genet. 2009;10: 23 10.1186/1471-2156-10-23 19473544PMC3224661 | β | β | β |
| MossHB, ChenCM, YiHY. Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. J Stud Alcohol Drugs. 2012;73(5): 820β28. 2284624610.15288/jsad.2012.73.820PMC3410949 | β | β | β |
| MwenifumboJC, TyndaleRF. Molecular genetics of nicotine metabolism. Handb Exp Pharmacol. 2009;192: 235β59. 10.1007/978-3-540-69248-5_9 19184652 | β | β | β |
| NaeemH, WongNC, ChattertonZ, HongMK, PedersenJS, CorcoranNM, et al Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics. 2014;15: 51 10.1186/1471-2164-15-51 24447442PMC3943510 | β | β | β |
| NakajimaM, FukamiT, YamanakaH, HigashiE, SakaiH, YoshidaR, et al Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80(3): 282β97. 1695249510.1016/j.clpt.2006.05.012 | β | β | β |
| NasarreP, PotironV, DrabkinH, RocheJ. Guidance molecules in lung cancer. Cell Adh Migr. 2010;4(1): 130β45. 2013969910.4161/cam.4.1.10882PMC2852570 | β | β | β |
| NealeMC, BokerSM, XieG, MaesHH (2006). Mx: Statistical Modeling. VCU Box 900126, Richmond, VA 23298: Department of Psychiatry 7th Edition. | β | β | β |
| OscarsonM, McLellanRA, AspV, LedesmaM, Bernal RuizML, SinuesB, et al Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat. 2002;20(4): 275β83. 1232502310.1002/humu.10126 | β | β | β |
| PattersonF, SchnollRA, WileytoEP, PintoA, EpsteinLH, ShieldsPG, et al Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3): 320β25. 10.1038/clpt.2008.57 18388868 | β | β | β |
| PurcellS, ChernySS, ShamPC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19(1): 149β50. 1249930510.1093/bioinformatics/19.1.149 | β | β | β |
| RaitakariOT, JuonalaM, RΓΆnnemaaT, Keltikangas-JΓ€rvinenL, RΓ€sΓ€nenL, PietikΓ€inenM, et al Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol. 2008;37(6): 1220β6. 10.1093/ije/dym225 18263651 | β | β | β |
| RayR, TyndaleRF, LermanC. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009;23(3): 252β61. 10.1080/01677060802572887 19169923PMC3772540 | β | β | β |
| RossS, PeselowE. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009;32(5): 269β76. 1983499210.1097/wnf.0b013e3181a9163c | β | β | β |
| SchnollRA, PattersonF, WileytoEP, TyndaleRF, BenowitzN, LermanC. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1): 6β11. 10.1016/j.pbb.2008.10.016 19000709PMC2657225 | β | β | β |
| SilverbergMS, ChoJH, RiouxJD, McGovernDP, WuJ, AnneseV, et al Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41(2): 216β20. 10.1038/ng.275 19122664PMC2652837 | β | β | β |
| St HelenG, NovalenM, HeitjanDF, DempseyD, JacobP3rd, AziziyehA, et al Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7): 1105β14. 10.1158/1055-9965.EPI-12-0236 22552800PMC3392523 | β | β | β |
| StrasserAA, BenowitzNL, PintoAG, TangKZ, HechtSS, CarmellaSG, et al Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011;20(2): 234β38. 10.1158/1055-9965.EPI-10-0674 21212060PMC3077576 | β | β | β |
| SwanGE, Lessov-SchlaggarCN, BergenAW, HeY, TyndaleRF, BenowitzNL. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19(5): 388β98. 10.1097/FPC.0b013e32832a404f 19300303PMC2849278 | β | β | β |
| Tanner J-A, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, et al. Agreement and association between measures of the nicotine metabolite ratio by different analytical approaches in plasma and urine: Implications for clinical implementation. Cancer Epidemiology, Biomarkers & Prevention, in press 10.1158/1055-9965.EPI-14-1381PMC452632626014804 | β | β | β |
| ThorgeirssonTE, GudbjartssonDF, SurakkaI, VinkJM, AminN, GellerF, et al Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5): 448β53. 10.1038/ng.573 20418888PMC3080600 | β | β | β |
| VairaV, FaversaniA, MartinNM, GarlickDS, FerreroS, NosottiM, et al Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res. 2013;73(8): 2695β2705. 10.1158/0008-5472.CAN-12-4232 23440423PMC3695627 | β | β | β |
| YamazakiH, InoueK, HashimotoM, ShimadaT. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999;73(2): 65β70. 1035018510.1007/s002040050588 | β | β | β |
| YingjieL, JianT, ChanghaiY, JingboL. Numblike regulates proliferation, apoptosis, and invasion of lung cancer cell. Tumour Biol. 2013;34(5): 2773β80. 10.1007/s13277-013-0835-7 23681800 | β | β | β |
| ZhongW, JiangMM, WeinmasterG, JanLY, JanYN. Differential expression of mammalian Numb, Numblike and Notch1 suggests distinct roles during mouse cortical neurogenesis. Development. 1997;124(10): 1887β97. 916983610.1242/dev.124.10.1887 | β | β | β |
| ZhouX, StephensM. Genome-wide efficient mixed-model analysis for association studies. Nat Genet. 2012;44(7): 821β24. 10.1038/ng.2310 22706312PMC3386377 | β | β | β |
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses. | Laaboub N et al. | β | 2026 | β |
| Integrating PBPK modeling and tobacco biomarkers to interpret N-(2-hydroxyethyl)valine (HEV) hemoglobin adducts in the U.S. population. | Lin YS et al. | β | 2026 | β |
| A phenome-wide association study of genetically determined nicotine metabolism reveals novel links with health-related outcomes. | Buchwald J et al. | β | 2025 | β |
| Extending Investigations of miR-126-5p on the Regulation of CYP2A6, the Major Nicotine-Inactivating Enzyme. | Gu W et al. | β | 2025 | β |
| Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers. | Pouget JG et al. | β | 2025 | β |
| Inhaled pollutants and neurological health via the lung-brain axis. | Li H et al. | β | 2025 | β |
| Nicotine Metabolism-Related Genetic Polymorphisms Associated with Smoking Cessation in Korean Men: A Candidate Gene Association Study in a Korean Cohort. | Park JM et al. | β | 2025 | β |
| Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders. | Kember RL et al. | β | 2024 | β |
| CYP2A6 Activity and Cigarette Consumption Interact in Smoking-Related Lung Cancer Susceptibility. | Du M et al. | β | 2024 | β |
| CYP2A6 associates with respiratory disease risk and younger age of diagnosis: a phenome-wide association Mendelian Randomization study. | Giratallah H et al. | β | 2024 | β |
| Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD. | Qin R et al. | β | 2024 | β |
| The genetic landscape of age-related hearing loss. | Ninoyu Y et al. | β | 2024 | β |
| Age, Period, and Cohort Analysis of Smoking Intensity Among Current Smokers in Malaysia, 1996-2015. | Teh CH et al. | β | 2023 | β |
| An in-depth association analysis of genetic variants within nicotine-related loci: Meeting in middle of GWAS and genetic fine-mapping. | Mo C et al. | β | 2023 | β |
| Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial. | Lee SS et al. | β | 2023 | β |
| Implication of DNA methylation during lifestyle mediated weight loss. | Aurich S et al. | β | 2023 | β |
| Pharmacogenomics: Driving Personalized Medicine. | Sadee W et al. | β | 2023 | β |
| Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy. | Singh RD et al. | β | 2023 | β |
| The use of biomarkers to guide precision treatment for tobacco use. | Siegel SD et al. | β | 2023 | β |
| Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. | Langlois AWR et al. | β | 2022 | β |
| Clinical Implication of Smoking-Related Aryl-Hydrocarbon Receptor Repressor (AHRR) Hypomethylation in Japanese Adults. | Takeuchi F et al. | β | 2022 | β |
| CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response. | Fang C et al. | β | 2022 | β |
| Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. | El-Boraie A et al. | β | 2022 | β |
| Genetic insights into smoking behaviours in 10,558 men of African ancestry from continental Africa and the UK. | Piga NN et al. | β | 2022 | β |
| Investigation of the genetic effect of 56 tobacco-smoking susceptibility genes on DNA methylation and RNA expression in human brain. | Yang Z et al. | β | 2022 | β |
| Predicting nicotine metabolism across ancestries using genotypes. | Baurley JW et al. | β | 2022 | β |
| The potential of DNA methylation as a biomarker for obesity and smoking. | Heikkinen A et al. | β | 2022 | β |
| Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. | Chenoweth MJ et al. | β | 2021 | β |
| Biochemistry of nicotine metabolism and its relevance to lung cancer. | Murphy SE | β | 2021 | β |
| Clarifying the Genetic Influences on Nicotine Dependence and Quantity of Use in Cigarette Smokers. | Verhulst B et al. | β | 2021 | β |
| Genetics of substance use disorders in the era of big data. | Gelernter J et al. | β | 2021 | β |
| Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. | Buchwald J et al. | β | 2021 | β |
| Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. | Hertz DL et al. | β | 2021 | β |
| Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. | Butler K et al. | β | 2021 | β |
| Influence of <i>CYP4F2</i>, <i>ApoE</i>, and <i>CYP2A6</i> gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan. | Al-Eitan LN et al. | β | 2021 | β |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | β | 2021 | β |
| Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke. | Schaefer KR et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| Pharmacogenomics: A road ahead for precision medicine in psychiatry. | PardiΓ±as AF et al. | β | 2021 | β |
| Predicting Nicotine Metabolism Across Ancestries Using Genotypes | Baurley JW et al. | β | 2021 | β |
| Role of CYP2A6 in Methimazole Bioactivation and Hepatotoxicity. | Li J et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. | Bray MJ et al. | β | 2020 | β |
| Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. | Muderrisoglu A et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. | Xu K et al. | β | 2020 | β |
| Identification of <i>slit3</i> as a locus affecting nicotine preference in zebrafish and human smoking behaviour. | GarcΓa-GonzΓ‘lez J et al. | β | 2020 | β |
| Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. | Erzurumluoglu AM et al. | β | 2020 | β |
| Opioid Use and Rate of Nicotine Metabolism Among Pregnant Smokers. | Oncken C et al. | β | 2020 | β |
| Translational Molecular Approaches in Substance Abuse Research. | Fulton SL et al. | β | 2020 | β |
| Validity assessment of self-reported smoking status in firefighters using the urine cotinine test. | Heo HC et al. | β | 2020 | β |
| Common and Rare Variants Genetic Association Analysis of Cigarettes per Day Among Ever-Smokers in Chronic Obstructive Pulmonary Disease Cases and Controls. | Lutz SM et al. | β | 2019 | β |
| Comparison of smoking-related DNA methylation between newborns from prenatal exposure and adults from personal smoking. | Sikdar S et al. | β | 2019 | β |
| Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. | Shahab L et al. | β | 2019 | β |
| Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. | Liakoni E et al. | β | 2019 | β |
| Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci. | Gupta R et al. | β | 2019 | β |
| Higher prevalence of hypertensive disorders of pregnancy in women who smoke: the Japan environment and children's study. | Tanaka K et al. | β | 2019 | β |
| Impact of Nicotine Replacement and Electronic Nicotine Delivery Systems on Fetal Brain Development. | Sailer S et al. | β | 2019 | β |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | β | 2019 | β |
| The effect of body mass index on smoking behaviour and nicotine metabolism: a Mendelian randomization study. | Taylor AE et al. | β | 2019 | β |
| The Older Finnish Twin Cohort - 45 Years of Follow-up. | Kaprio J et al. | β | 2019 | β |
| Using DNA methylation to validate an electronic medical record phenotype for smoking. | McGinnis KA et al. | β | 2019 | β |
| Using genomic profiling for understanding and improving response to smoking cessation treatment. | Bierut LJ | β | 2019 | β |
| Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers: A Nonrandomized Clinical Trial. | Mercincavage M et al. | β | 2018 | β |
| Biochemical, demographic, and self-reported tobacco-related predictors of the acute heart rate response to nicotine in smokers. | Jensen KP et al. | β | 2018 | β |
| Biosignature Discovery for Substance Use Disorders Using Statistical Learning. | Baurley JW et al. | β | 2018 | β |
| Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. | Chenoweth MJ et al. | β | 2018 | β |
| Human Genetics of Addiction: New Insights and Future Directions. | Hancock DB et al. | β | 2018 | β |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | β | 2018 | β |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| Smoking induces coordinated DNA methylation and gene expression changes in adipose tissue with consequences for metabolic health. | Tsai PC et al. | β | 2018 | β |
| The PHD1 oxygen sensor in health and disease. | Kennel KB et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | β | 2018 | β |
| A Novel Tobacco Use Phenotype Suggests the 15q25 and 19q13 Loci May be Differentially Associated With Cigarettes per Day and Tobacco-Related Problems. | Richmond-Rakerd LS et al. | β | 2017 | β |
| Cigarette Smoking, Diabetes, and Diabetes Complications: Call for Urgent Action. | Zhu P et al. | β | 2017 | β |
| CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study. | Yuan JM et al. | β | 2017 | β |
| Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. | Hosono H et al. | β | 2017 | β |
| Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. | PΓ©rez-Rubio G et al. | β | 2017 | β |
| Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci. | Pintarelli G et al. | β | 2017 | β |
| Pathways to smoking behaviours: biological insights from the Tobacco and Genetics Consortium meta-analysis. | MinicΓ£ CC et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Phenome-wide association study for CYP2A6 alleles: rs113288603 is associated with hearing loss symptoms in elderly smokers. | Polimanti R et al. | β | 2017 | β |
| Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | Tanner JA et al. | β | 2017 | β |
| Significant association of the CHRNB3-CHRNA6 gene cluster with nicotine dependence in the Chinese Han population. | Wen L et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| A Test-Replicate Approach to Candidate Gene Research on Addiction and Externalizing Disorders: A Collaboration Across Five Longitudinal Studies. | Samek DR et al. | β | 2016 | β |
| Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions. | Yang J et al. | β | 2016 | β |
| Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study. | Yuan JM et al. | β | 2016 | β |
| Genetics of Substance Use Disorders. | Yu C et al. | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. | Cornelis MC et al. | β | 2016 | β |
| Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. | Patel YM et al. | β | 2016 | β |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | β | 2016 | β |
| Sex-dichotomous effects of NOS1AP promoter DNA methylation on intracranial aneurysm and brain arteriovenous malformation. | Wang Z et al. | β | 2016 | β |